Navigation Links
Cardium Presents First Quarter 2012 Financial Results and Recent Developments
Date:5/15/2012

SAN DIEGO, May 15, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today presented its financial results for the first quarter ended March 31, 2012, and other recent developments.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

In addition to the announcement of first quarter 2012 financial results, Cardium reported its goals for 2012, which were outlined in the year-end report, and include (1) plans to advance commercialization of its new Excellagen® advanced, physician-use wound care product through strategic partners in the U.S., as well as internationally; (2) develop new product extensions based on Excellagen's formulated collagen product platform for additional wound healing applications; (3) advance of its ASPIRE Generx® clinical study at leading medical centers in the Russian Federation for patients with advanced coronary disease; (4) introduce additional product line extensions and broaden national distribution of the Company's MedPodium® healthy lifestyle product platform; and (5) continue to identify and evaluate businesses, product opportunities and technologies for potential acquisition on favorable economic terms consistent with the Company's long-term business strategy.

First Quarter 2012 Financial HighlightsThe Company's research and development costs for the three months ended March 31, 2012 totaled $1.2 million and selling, general and administrative expenses were $1.5 million, compared to $492,000 and $1.3 million, respectively, for the same period last year. The increase in expenses related to development costs associated with testing and validation of our Excellagen product, the initiation of the Generx ASPIRE study, and marketing efforts for the new FDA-cleared Excellagen product and the MedPodium Nutra-Apps® product li
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium to Present at Upcoming Investor Conferences
2. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Amex
3. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
4. Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
5. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
6. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
7. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
8. Cardium Regains Listing Compliance With NYSE Amex
9. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
10. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
11. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... SCHOFIELD, Wis. , May 23, 2013 /PRNewswire/ ... a researcher, developer, and marketer of over-the-counter (OTC) ... re-issued its research opinion on the company based ... Highlights , Non-Prescription, All Natural Product ... Show the Product Outperforms #1 Prescription Competitor ...
(Date:5/23/2013)... 2013  Saddleback Memorial Medical Center in ... hospital on the West Coast to perform a hysterectomy ... provides women with a state-of-the-art, minimally invasive approach to ... , M.D., a highly regarded Orange ... of minimally invasive surgery at Saddleback Memorial, led the ...
(Date:5/23/2013)... May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... DCVax ® personalized immune therapies for solid tumor ... at this year,s American Society Of Clinical Oncology (ASCO) ... its leadership role in immune therapy.  (Logo: ... meeting is the pre-eminent conference focused on clinical treatment ...
(Date:5/23/2013)... , May 23, 2013 Pusan ... Inc., a private biotherapeutics and contract research company ... products for cancer, announced today a publication reporting ... treated with the oncolytic and immunotherapeutic vaccinia JX-594 ... research was published in the May 15 th ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... KVISTGAARD, Denmark, September 22 Bavarian,Nordic A/S ... European Cancer Organisation (ECCO), ECCO 15 - 34th ESMO ... data from a Phase II double-blind, prospective randomized,placebo-controlled study ... Dr. Wayne Godfrey, Senior Medical Director, BN,ImmunoTherapeutics. , ...
... 22 Micromet, Inc. (Nasdaq: MITI ), a ... cancer, inflammation and autoimmune diseases, today announced the appointment of ... Medical Officer effective November 1, 2009. , ... and has more than 20 years of experience in clinical ...
... , SEATTLE, Sept. 22 Cell ... has been added to the NASDAQ OMX Global Biotechnology Index (NASDAQ: ... prior to the market open on September 21, 2009. , ... modified market-capitalization weighted index designed to track the performance of the ...
Cached Biology Technology:New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 2New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 3Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 2Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 3Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 4Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index 2
(Date:5/24/2013)... in the ongoing public health debate is the lack ... nutrient dense. A new study, "Vegetable Cost Metrics ... Penny," published in the journal PLOS ONE , ... values in the produce aisle, providing one of the ... vegetables and delivering one of the most affordable source ...
(Date:5/24/2013)... studying noise in one French Quarter neighborhood of New ... municipal ordinances, Annette Hurley, PhD, Assistant Professor of Audiology ... Arriaga, a third-year LSUHSC doctor of audiology student, recommend ... hearing health. Their case study is published online in ... Management ., "An important part of an audiologist,s practice ...
(Date:5/23/2013)... RICHLAND, Wash. Pacific Northwest National Laboratory honored ... and commercialization of intellectual property at PNNL,s annual ... , The Department of Energy national laboratory ... Year for his work developing battery materials that ... to the electrical grid, and reduce the time ...
Breaking Biology News(10 mins):New research shows that potatoes provide one of the best nutritional values per penny 2Please do try this at home 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... NY, April 29, 2011Videoscopy, a groundbreaking new ... Journal of Laparoendoscopic & Advanced Surgical ... Ann Liebert, Inc., publishers ( http://www.liebertpub.com ). ... surgical and microinvasive demonstrations of the latest ...
... team of scientists has produced an innovative new study of ... April issue of the journal Ecological Applications . ... both of UC Santa Barbara,s Department of Geography. They analyzed ... a study of 3,100 households in the cities of Minneapolis ...
... , , , , , , , ... , , , ... which is about one millisecond long. Several fish can be heard in... , ... , , , , , , ...
Cached Biology News:Groundbreaking minimally invasive surgical videojournal launched by Mary Ann Liebert Inc. 2UCSB urban ecosystem research featured in leading ecology journal 2UCSB urban ecosystem research featured in leading ecology journal 3Jump in communication skills led to species explosion in electric fishes 2Jump in communication skills led to species explosion in electric fishes 3Jump in communication skills led to species explosion in electric fishes 4Jump in communication skills led to species explosion in electric fishes 5Jump in communication skills led to species explosion in electric fishes 6Jump in communication skills led to species explosion in electric fishes 7
... cAMP - [125I] Direct SPA ... SPA.Includes lysis reagents that eliminate lengthy ... cAMP measurement (optional use).Range: 1.32-84.28 ng/ml ... pmol/ml).Overnight protocol.Store at 2-8 C. Category: ...
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
... synthase, cytoplasmic (C1-THF ... dehydrogenase (EC 1.5.1.5); ... 3.5.4.9); Formyltetrahydrofolate synthetase ... ...
...
Biology Products: